Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.

Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, Gedeon PC, Snyder DJ, Herndon JE 2nd, Healy P, Reap EA, Archer GE, Fecci PE, Sampson JH, Sanchez-Perez L.

Clin Cancer Res. 2019 Jan 1;25(1):358-368. doi: 10.1158/1078-0432.CCR-18-1211. Epub 2018 Nov 13.

PMID:
30425092
2.

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy PN, Herndon JE 2nd, McLendon RE, Keir ST, Archer GE, Reap EA, Sanchez-Perez L, Bigner DD, Sampson JH.

Clin Cancer Res. 2018 Aug 1;24(15):3611-3631. doi: 10.1158/1078-0432.CCR-17-0126. Epub 2018 Apr 27.

3.

A Supramolecular Vaccine Platform Based on α-Helical Peptide Nanofibers.

Wu Y, Norberg PK, Reap EA, Congdon KL, Fries CN, Kelly SH, Sampson JH, Conticello VP, Collier JH.

ACS Biomater Sci Eng. 2017 Dec 11;3(12):3128-3132. doi: 10.1021/acsbiomaterials.7b00561. Epub 2017 Sep 11.

4.

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE 2nd, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, Hossain-Ibrahim MK, Saraswathula A, Nair SK, Dunn-Pirio AM, Broome TM, Weinhold KJ, Desjardins A, Vlahovic G, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Fecci PE, Mitchell DA, Sampson JH.

Cancer Res. 2018 Jan 1;78(1):256-264. doi: 10.1158/0008-5472.CAN-17-0469. Epub 2017 Nov 1.

5.

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.

Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE 2nd, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, Mitchell DA, Sampson JH.

Clin Cancer Res. 2017 Apr 15;23(8):1898-1909. doi: 10.1158/1078-0432.CCR-16-2057.

6.

Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.

Saraswathula A, Reap EA, Choi BD, Schmittling RJ, Norberg PK, Sayour EJ, Herndon JE 2nd, Healy P, Congdon KL, Archer GE, Sanchez-Perez L, Sampson JH.

Cancer Immunol Immunother. 2016 Feb;65(2):205-11. doi: 10.1007/s00262-015-1784-3. Epub 2016 Jan 12.

7.

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH.

Nature. 2015 Mar 19;519(7543):366-9. doi: 10.1038/nature14320. Epub 2015 Mar 11.

8.

Immunotherapy for malignant glioma.

Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, Sampson JH.

Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S68-77. doi: 10.4103/2152-7806.151341. eCollection 2015.

9.

Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.

Sanchez-Perez L, Suryadevara CM, Choi BD, Reap EA, Sampson JH.

Oncoimmunology. 2014 Jul 3;3(7):e944054. eCollection 2014.

10.

Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Choi BD, Gedeon PC, Herndon JE 2nd, Archer GE, Reap EA, Sanchez-Perez L, Mitchell DA, Bigner DD, Sampson JH.

Cancer Immunol Res. 2013 Sep;1(3):163. doi: 10.1158/2326-6066.CIR-13-0049.

11.

EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.

Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE 2nd, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA.

Clin Cancer Res. 2014 Feb 15;20(4):972-84. doi: 10.1158/1078-0432.CCR-13-0709. Epub 2013 Dec 18.

12.

BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Sanchez-Perez L, Choi BD, Reap EA, Sayour EJ, Norberg P, Schmittling RJ, Archer GE, Herndon JE 2nd, Mitchell DA, Heimberger AB, Bigner DD, Sampson JH.

Cancer Immunol Immunother. 2013 Jun;62(6):983-7. doi: 10.1007/s00262-013-1405-y. Epub 2013 Apr 17.

13.

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA.

Hum Gene Ther. 2012 Oct;23(10):1043-53. doi: 10.1089/hum.2012.041. Epub 2012 Sep 24.

14.

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Mitchell DA.

PLoS One. 2012;7(2):e31046. doi: 10.1371/journal.pone.0031046. Epub 2012 Feb 27.

15.

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF, Chulay JD.

Vaccine. 2009 Dec 11;28(2):484-93. doi: 10.1016/j.vaccine.2009.09.135. Epub 2009 Oct 24.

PMID:
19857446
16.

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, Kamrud KI, Copp L, Lewis W, Cecil C, Norberg P, Wagner J, Watson A, Negri S, Burnett BK, Graham A, Smith JF, Chulay JD.

Vaccine. 2007 Nov 23;25(48):8180-9. Epub 2007 Oct 5.

17.

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Reap EA, Morris J, Dryga SA, Maughan M, Talarico T, Esch RE, Negri S, Burnett B, Graham A, Olmsted RA, Chulay JD.

Vaccine. 2007 Oct 16;25(42):7441-9. Epub 2007 Aug 30.

18.

Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Reap EA, Dryga SA, Morris J, Rivers B, Norberg PK, Olmsted RA, Chulay JD.

Clin Vaccine Immunol. 2007 Jun;14(6):748-55. Epub 2007 Apr 18.

19.

Characterization and selection of HIV-1 subtype C isolates for use in vaccine development.

Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, Thomas R, Reap EA, Cilliers T, van Harmelen J, Pascual A, Ramjee G, Gray G, Johnston R, Karim SA, Swanstrom R.

AIDS Res Hum Retroviruses. 2003 Feb;19(2):133-44.

PMID:
12639249
20.

Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase.

Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, Earp HS, Matsushima G, Reap EA.

J Exp Med. 2002 Jul 1;196(1):135-40.

21.

Phagocytosis and clearance of apoptotic cells is mediated by MER.

Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, Matsushima GK.

Nature. 2001 May 10;411(6834):207-11.

PMID:
11346799
22.

B cell subsets in pristane-induced autoimmunity.

Richards HB, Reap EA, Shaw M, Satoh M, Yoshida H, Reeves WH.

Curr Top Microbiol Immunol. 2000;252:201-7. No abstract available.

PMID:
11125477
23.

The role of environmental antigens in the spontaneous development of autoimmunity in MRL-lpr mice.

Maldonado MA, Kakkanaiah V, MacDonald GC, Chen F, Reap EA, Balish E, Farkas WR, Jennette JC, Madaio MP, Kotzin BL, Cohen PL, Eisenberg RA.

J Immunol. 1999 Jun 1;162(11):6322-30.

24.

Expression and function of Fas on cells damaged by gamma-irradiation in B6 and B6/lpr mice.

Booker JK, Reap EA, Cohen PL.

J Immunol. 1998 Nov 1;161(9):4536-41.

25.

Fas/Fas ligand interactions are involved in ultraviolet-B-induced human lymphocyte apoptosis.

Caricchio R, Reap EA, Cohen PL.

J Immunol. 1998 Jul 1;161(1):241-51.

26.

Novel immunoregulatory B cell pathways revealed by lpr-+ mixed chimeras.

Sobel ES, Kakkanaiah VN, Schiffenbauer J, Reap EA, Cohen PL, Eisenberg RA.

J Immunol. 1998 Feb 1;160(3):1497-503.

27.

Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions.

Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL.

Proc Natl Acad Sci U S A. 1997 May 27;94(11):5750-5.

28.

Markedly diminished radiation-induced lymphocyte apoptosis in lpr mice suggests a role for Fas in eliminating damaged cells.

Reap EA, Roof K, Maynor K, Cohen PL.

Ann N Y Acad Sci. 1997 Apr 5;815:116-8. No abstract available.

PMID:
9186646
29.

MHC genes modify systemic autoimmune disease. The role of the I-E locus.

Creech EA, Nakul-Aquaronne D, Reap EA, Cheek RL, Wolthusen PA, Cohen PL, Eisenberg RA.

J Immunol. 1996 Jan 15;156(2):812-7.

PMID:
8543837
30.

Phenotypic abnormalities of splenic and bone marrow B cells in lpr and gld mice.

Reap EA, Piecyk ML, Oliver A, Sobel ES, Waldschmidt T, Cohen PL, Eisenberg RA.

Clin Immunol Immunopathol. 1996 Jan;78(1):21-9.

PMID:
8599880
31.

bcl-2 transgenic Lpr mice show profound enhancement of lymphadenopathy.

Reap EA, Felix NJ, Wolthusen PA, Kotzin BL, Cohen PL, Eisenberg RA.

J Immunol. 1995 Dec 1;155(11):5455-62.

PMID:
7594564
32.

Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice.

Reap EA, Leslie D, Abrahams M, Eisenberg RA, Cohen PL.

J Immunol. 1995 Jan 15;154(2):936-43.

PMID:
7529292
33.

The role of B cell abnormalities in the systemic autoimmune syndromes of lpr and gld mice.

Eisenberg RA, Sobel ES, Reap EA, Halpern MD, Cohen PL.

Semin Immunol. 1994 Feb;6(1):49-54. Review.

PMID:
8167307
34.

Conventional B cells, not B1 cells, are the source of autoantibodies in chronic graft-versus-host disease.

Reap EA, Sobel ES, Jennette JC, Cohen PL, Eisenberg RA.

J Immunol. 1993 Dec 15;151(12):7316-23.

PMID:
7505027
35.

Conventional B cells, not B-1 cells, are responsible for producing autoantibodies in lpr mice.

Reap EA, Sobel ES, Cohen PL, Eisenberg RA.

J Exp Med. 1993 Jan 1;177(1):69-78.

36.

The role of CD5+ B cells in the production of autoantibodies in murine systemic lupus erythematosus.

Reap EA, Sobel ES, Cohen PL, Eisenberg RA.

Ann N Y Acad Sci. 1992 May 4;651:588-90. No abstract available.

PMID:
1376085
37.

Stimulation of the immune response by dimethylglycine, a nontoxic metabolite.

Reap EA, Lawson JW.

J Lab Clin Med. 1990 Apr;115(4):481-6.

PMID:
1691258
38.

The effects of cyclosporine on acute murine Coxsackie B3 myocarditis.

O'Connell JB, Reap EA, Robinson JA.

Circulation. 1986 Feb;73(2):353-9.

PMID:
3943167
39.

A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis.

Costanzo-Nordin MR, Reap EA, O'Connell JB, Robinson JA, Scanlon PJ.

J Am Coll Cardiol. 1985 Nov;6(5):1078-82.

Supplemental Content

Support Center